TIDMSLN
Silence Therapeutics PLC
04 May 2021
Silence Therapeutics Launches New Video Game to Support
International Thalassemia Day and Raise Disease Awareness
- Play the free online game and share your score on social #BloodRunBeta
- Silence partners with Thalassaemia International Federation
(TIF) to support May 8(th) awareness day activities - join the
conversation on social media #ITD2021
4 May 2021
LONDON, Silence Therapeutics plc , AIM: SLN and Nasdaq: SLN ("
Silence " or " the Company "), a leader in the discovery,
development and delivery of novel short interfering ribonucleic
acid (siRNA) therapeutics for the treatment of diseases with
significant unmet medical need, today announced the launch of a
new, retro-inspired, online game to raise awareness of the rare
blood disorder, thalassemia, ahead of International Thalassemia Day
on Saturday May 8(th) 2021.
'Blood Run Beta' ( www.bloodrunbeta.game ) is a free game now
available for people of all ages to play and learn more about the
daily impact of thalassemia and one of its most common symptoms -
fatigue. The aim of the game is to get as far as possible without
the energy meter reaching zero, avoiding everyday obstacles that
consume energy and 'powering up' by finding blood drops. The latter
represent blood transfusions - one of the main treatment options
for people with more severe forms of the disease. Everyone is
encouraged to post their scores on social media using the hashtag
#BloodRunBeta. By sharing the game on social media, Silence aims to
draw public attention to this underrecognized community with high
unmet need.
In addition, Silence is proud to be sponsoring the Thalassaemia
International Federation (TIF)'s International Thalassemia Day
(ITD) activities. ITD is a global event which takes place on May
8(th) each year, organized by TIF. It marks an opportunity for
patient advocacy groups, charities, healthcare professionals,
pharma/biotech companies and individuals around the world to unite
in raising awareness of the condition through a variety of
activities. The theme for this year is "Addressing Health
Inequalities Across the Global Thalassemia Community" and the
public can join in and show their support largely through social
media, using the hashtag #ITD2021.
Giles Campion, MD, EVP, Head of R&D and Chief Medical
Officer of Silence Therapeutics said: "Thalassemia is a central
focus of our research and while great strides have been made in
recent years to raise awareness of the condition, there is still
more that can be done. The burden of the disease and current
treatment options that can be highly disruptive to daily life for
patients and their families are often underrecognized. We are proud
to partner with the thalassemia community and support better
understanding of this often overlooked condition."
Dr Androulla Eleftheriou (TIF Executive Director) of
Thalassaemia International Federation said: "International
Thalassemia Day allows us to commemorate those who are no longer
with us and to strengthen the efforts as well as commend those
fighting for the right to a better quality of life and equal care
across the globe. Increasing public awareness of the condition in
new and creative ways is important as we expand our advocacy reach
and put thalassemia on the health policy agenda of countries around
the world. We are grateful to have partners like Silence who help
us further our mission to support affected families on a global
scale."
Enquiries:
Silence Therapeutics plc Tel: +1 (646) 637-3208
Gem Hopkins, Head of IR and Corporate Communications
ir@silence-therapeutics.com
European PR Tel: +44 (0) 20 3709
Consilium Strategic Communications 5700
Mary-Jane Elliott/ Angela Gray / Chris
Welsh
silencetherapeutics@consilium-comms.com
About Thalassemia
Thalassemia is an inherited condition which prevents a person's
bone marrow from producing enough healthy red blood cells. Red
blood cells carry oxygen from the lungs to all of the cells in the
body to help them work normally. There are a number of different
types of thalassemia, such as beta-thalassemia. The types vary from
a very mild form to a severe disease that can be life-threatening
if untreated. Current treatments can usually keep the symptoms
under control do not treat the underlying cause of thalassemia or
prevent it from progressing. Treatment to manage symptoms often
requires regular hospital appointments that can disrupt normal
life. More information about Thalassemia including quotes from
patients about what it is like to live with the condition can be
found here .
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
medical need. Silence's proprietary mRNAi GOLD(TM) platform can be
used to create siRNAs that precisely target and silence
disease-associated genes in the liver, which represents a
substantial opportunity. Silence's wholly owned product candidates
include SLN360 designed to address the high and prevalent unmet
medical need in reducing cardiovascular risk in people born with
high levels of lipoprotein(a) and SLN124 designed to address iron
loading anemias. Silence also maintains ongoing research and
development collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals, and Takeda, among others. For more information,
please visit https://www.silence-therapeutics.com/ .
About TIF
The Thalassaemia International Federation (TIF) is a non-profit,
non-governmental organization founded in 1986 by a small group of
patients and parents. Its vision is to ensure equal access to
quality health care for every patient with thalassemia and other
hemoglobin disorders across the world, with a mission is to promote
and implement national control programs for the prevention and
treatment of thalassemia and other hemoglobin disorders in every
affected country. TIF has a wealth of resources and provides links
to local organizations around the world, to help patients or family
members find support in their own country.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements, including with respect to the Company's clinical
development timeline and commercial prospects. These
forward-looking statements are not historical facts but rather are
based on the Company's current expectations, estimates, and
projections about its industry; its beliefs; and assumptions. Words
such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,'
'seeks,' 'estimates,' and similar expressions are intended to
identify forward-looking statements. These statements are not
guarantees of future performance and are subject to known and
unknown risks, uncertainties, and other factors, some of which are
beyond the Company's control, are difficult to predict, and could
cause actual results to differ materially from those expressed or
forecasted in the forward-looking statements, including the
potential impact of COVID-19 on the Company's clinical development
and regulatory timelines and plans. The Company cautions security
holders and prospective security holders not to place undue
reliance on these forward-looking statements, which reflect the
view of the Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABXLLBFELFBBZ
(END) Dow Jones Newswires
May 04, 2021 02:00 ET (06:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Dec 2024 to Jan 2025
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Jan 2024 to Jan 2025
